| Name | Title | Contact Details |
|---|
Tobira Therapeutics is a clinical-stage biopharmaceutical company developing cenicriviroc (CVC), an oral potent dual inhibitor of chemokine receptors CCR2 and CCR5. Tobira is initiating a Phase 2 clinical trial of cenicriviroc for the treatment of Nonalcoholic Steatohepatitis (NASH), a leading cause of cirrhosis and liver transplant. The company has also completed a Phase 2b clinical trial of cenicriviroc in 143 HIV-infected subjects, and the compound is positioned for Phase 3 studies as a novel, once daily, fixed-dose cenicriviroc/lamivudine backbone as part of combination HIV therapy. Tobira is backed by a syndicate of leading life science investors including Domain Associates, Frazier Healthcare Ventures, Montreux Equity Partners, Novo Ventures and Canaan Partners.
TMSi is specialized in developing of high-quality measurement systems for electrophysiological parameters such as EEG and High Density EMG. Our systems are highly versatile and have the best data quality possible.
Xiros turn bright ideas into brilliant implants. We are on a mission to improve patient outcomes by creating innovative implantable textiles and devices.
Quartesian delivers quality, expertise, and speed so you can master your data to take control of your clinical trial.
Macrolide Pharmaceuticals is a next-generation antibiotics company developing macrolides that are first-in-class with Gram-negative activity and will have broad applicability across multiple resistant infectious diseases.